Amgen Inc. Announces Board Changes and Executive Appointments

TL;DR

Amgen's board is shaking up: Bradway out, Pyott and Williams in, plus new execs and pay tweaks.

AI Summary

On May 31, 2024, Amgen Inc. filed an 8-K report detailing the departure of director Robert Bradway and the election of new directors, including David E.I. Pyott and R. Sanders Williams. The filing also announced the appointment of new officers and adjustments to compensatory arrangements for certain executives.

Why It Matters

Changes in board composition and executive roles can signal shifts in company strategy, governance, and future leadership direction.

Risk Assessment

Risk Level: low — This filing primarily concerns routine corporate governance changes and executive appointments, which typically carry low inherent risk.

Key Players & Entities

• Amgen Inc. (company) — Registrant
• Robert Bradway (person) — Departing Director
• David E.I. Pyott (person) — Elected Director
• R. Sanders Williams (person) — Elected Director
• May 31, 2024 (date) — Date of Report

FAQ

From the Filing

0001193125-24-153221.txt : 20240603 0001193125-24-153221.hdr.sgml : 20240603 20240603171735 ACCESSION NUMBER: 0001193125-24-153221 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240531 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 241014945 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 d827769d8k.htm 8-K 8-K AMGEN INC false 0000318154 0000318154 2024-05-31 2024-05-31 0000318154 us-gaap:CommonStockMember 2024-05-31 2024-05-31 0000318154 us-gaap:SeniorNotesMember 2024-05-31 2024-05-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2024 Amgen Inc. (Exact name of registrant as specified in its charter)   Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)     One Amgen Center Drive Thousand Oaks California     91320-1799          (Address of principal executive offices)     (Zip Code)       Registrant’s telephone number, including area code (805) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026   AMGN26   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Board of Directors of Amgen Inc. (the “ Company ”) previously adopted, subject to stockholder approval, the Amgen Inc. Second Amended and